Dendritic cell-based immunotherapy for prostate cancer.
Dendritic cell-based immunotherapy for prostate cancer.
复制标题
DOI：
10.1155/2010/517493
复制
发表时间：
2010
影响因子：
--
通讯作者：
Schmitz M
中科院分区：
文献类型：
--
作者：
Jähnisch H;Füssel S;Kiessling A;Wehner R;Zastrow S;Bachmann M;Rieber EP;Wirth MP;Schmitz M
树突状细胞（dc）是一种专业的抗原呈递细胞（apc），具有诱导、维持和调节t细胞反应的非凡能力，为基于dc的癌症疫苗接种策略提供了机会。因此，对前列腺癌患者进行了临床试验，其基础是给药带有肿瘤相关抗原的dc。这些临床试验表明，基于dc的免疫治疗策略是诱导前列腺癌患者免疫和临床反应的安全可行的概念。在这种情况下，由包括APCs在内的自体外周血单核细胞组成的sipuleucel-T疫苗，在体外预先暴露于融合蛋白PA2024，可延长转移性去势抵抗前列腺癌患者的总生存期。2010年4月，sipuleucel-T被美国食品和药物管理局批准用于前列腺癌治疗。
Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistent prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.
登录
查看更多内容
影响因子：
254.7
作者：
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者：
Thun, Michael J.
影响因子：
6.2
作者：
Higano, Celestia S.;Schellhammer, Paul F.;Frohlich, Mark W.
通讯作者：
Frohlich, Mark W.
影响因子：
10.3
作者：
Correale, P;Walmsley, K;Tsang, KY
通讯作者：
Tsang, KY
影响因子：
4.4
作者：
Heiser, A;Dahm, P;Vieweg, J
通讯作者：
Vieweg, J
影响因子：
8
作者：
Gu, Z;Thomas, G;Reiter, RE
通讯作者：
Reiter, RE